OVID - Ovid Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
10.28
-0.72 (-6.55%)
At close: 4:00PM EDT

10.28 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close11.00
Open11.11
Bid8.30 x 900
Ask10.49 x 800
Day's Range10.13 - 11.43
52 Week Range5.28 - 12.44
Volume85,751
Avg. Volume40,500
Market Cap253.13M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-1.90
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.50
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    Ovid Therapeutics Announces Presentations Related to OV101 Fragile X Syndrome Program at the 16th National Fragile X Foundation (NFXF) International Conference

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced several presentations related to the OV101 Fragile X syndrome program will be given this week at the 16th NFXF International Fragile X conference taking place in Cincinnati, Ohio from July 11 – 15, 2018. OV101 is a novel delta (δ)-selective GABAA receptor agonist that targets the disruption of tonic inhibition, a central physiological process of the brain that is thought to be the underlying cause of Fragile X syndrome and other neurodevelopmental disorders. It is believed that OV101 is the first investigational medicine to target the disruption of tonic inhibition.

  • GlobeNewswire5 days ago

    Ovid Therapeutics Announces Initiation of Phase 2 ROCKET Clinical Trial to Evaluate OV101 in Fragile X Syndrome

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has initiated the Phase 2 ROCKET clinical trial evaluating OV101 for the treatment of adolescents and young adult males with Fragile X syndrome. OV101 is a novel delta (δ)-selective GABAA receptor agonist that targets the disruption of tonic inhibition, a central physiological process of the brain that is thought to be the underlying cause of Fragile X syndrome and other neurodevelopmental disorders. It is believed that OV101 is the first investigational medicine to target the disruption of tonic inhibition.

  • GlobeNewswire2 months ago

    Ovid Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference on June 8, 2018

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will present a corporate overview at the Jefferies 2018 Global Healthcare Conference on Friday, June 8, 2018 at 9:30 a.m. ET. Ovid Therapeutics (OVID) is a New York-based biopharmaceutical company using its BoldMedicine™ approach to develop medicines that transform the lives of people with rare neurological disorders.

  • GlobeNewswire2 months ago

    Ovid Therapeutics Announces Two Oral Presentations at the 14th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV)

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Matthew During, M.D., DSc., founder, president and chief scientific officer of Ovid Therapeutics, will give two oral presentations at the 14th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV), taking place in Madrid, Spain. The presentations will describe new preclinical findings for TAK-935/OV935, an inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H), in a Phase 1b/2a clinical trial for dEE and OV329, an inactivator of GABA aminotransferase (GABA-AT), in preclinical development.

  • GlobeNewswire2 months ago

    Ovid Therapeutics Reports First Quarter 2018 Financial Results and Corporate Progress

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today reported financial results for the quarter ended March 31, 2018 and provided an overview of the company’s recent business progress. “We have an exceptionally talented team at Ovid, and I could not be more pleased with their continued clinical and operational execution,” said Jeremy Levin, DPhil, MB, BChir, chairman and chief executive officer of Ovid. “In the second half of the year, we expect to generate a rich set of data that will provide us with important information on the profile and potential of OV101 as a treatment for Angelman syndrome and TAK-935/OV935 as a treatment for dEE.

  • GlobeNewswire2 months ago

    Ovid Therapeutics to Present at Deutsche Bank’s 43rd Annual Health Care Conference on May 9, 2018

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today announced that management will present a corporate overview at Deutsche Bank’s 43rd Annual Health Care Conference on Wednesday, May 9, 2018 at 10:40 a.m. ET. Ovid Therapeutics (OVID) is a New York-based biopharmaceutical company using its BoldMedicine™ approach to develop therapies that transform the lives of patients with rare neurological disorders. Ovid’s drug candidate, OV101, is currently in development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid initiated the Phase 2 STARS trial of OV101 in people with Angelman syndrome in 2017 and completed a Phase 1 trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of epileptic encephalopathies and in 2017 initiated a Phase 1b/2a trial of OV935.

  • ACCESSWIRE3 months ago

    Wired News – Axsome Therapeutics Initiated Phase-2 Clinical Trial of AXS-05 in Smoking Cessation

    LONDON, UK / ACCESSWIRE / April 25, 2018 / Active-Investors.com has just released a free research report on Axsome Therapeutics, Inc. (NASDAQ: AXSM). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AXSM as the Company's latest news hit the wire. On April 23, 2018, the Company announced that it has enrolled first patient into a Phase-2 trial assessing AXS-05 for smoking cessation treatment.

  • ACCESSWIRE3 months ago

    Wired News - Clementia Commenced Phase-2 MO-Ped Trial for Palovarotene in Pediatric Patients with Multiple Osteochondromas

    Stock Monitor: Ovid Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 24, 2018 / Active-Investors.com has just released a free research report on Clementia Pharma Inc. (NASDAQ: CMTA ...